English
中文
Top search
Atopic dermatitis Chronic prurigo Epidermolysis bullosa Psoriasis Immune-mediated kidney disease Glaucoma
About Us Development course
Approaching PrimeGene Coporate culture Development course Top management Honors & qualifications
Development course

PrimeGene focuses on inflammatory-immune disease, and is committed to offering better therapy
options for patients around the world.

2016year09month
2017year06month
2021year03month
2022year08month
2022year12month
2023year05month
2023year12month
2016
September: PrimeGene was founded.
2017
June: The innovative drug R&D team was established.
2021
May: The first IND application was approved.
2022
August: A+ round of financing was completed.
2022
December: The Company got listed in the NEEQ market.
2023
May-October: the company obtained 7 clinical approvals
2023
December: the company completed a Phase IIb clinical trial and
closed nearly $100 million in Series B financing
About us
Approaching PrimeGene Coporate culture Development course Top management Honors & qualifications
Scientific research
Scientific and technological innovation Therapeutic area Product lines Win-win cooperation
News
Company News Industry trends
Recruitment
Philosophy on personnel Job duties
Get in touch with us
Floor 5&6, Tower B, Chongxin Building, Hangfeng Road 13#, Fengtai District, Beijing
010-83141848
Copyright owner：Prime Gene Therapeutics Co.,Ltd.
Copyright © 2023 All Rights Reserved.京ICP备2022001152号-1
Contact us Sitemap Privacy policy Legal statement